A Colorado physician is working to separate scientific promise from clinical reality in the fast-moving field of psychedelic medicine.
DENVER, CO, UNITED STATES, October 16, 2026 /EINPresswire.com/ — Dr. Lynn Puana, MD, who founded Premier Integrative & Cognitive Medical Institute (PICMI) and S&G Labs, is working to bridge the gap between psilocybin research and actual patient care. Her efforts span collaborative studies, individualized treatment plans, and educational outreach, all aimed at grounding psychedelic medicine in solid science while exploring its potential for brain health, mental health, and chronic pain.
The initiative combines laboratory work, clinical evaluations, and patient-reported outcomes to study how psilocybin might affect neuroplasticity, cognitive function, and the biological pathways tied to mental health. The goal is to produce data that can shape future research—while carefully distinguishing what is scientifically plausible from what is already proven in clinical settings.
Also worth a look: Quick Strike Media bets on AI-assisted SEO to keep small businesses visible in AI search and Cryonics Institute marks 50 years with 295 patients preserved, signaling growing interest in life extension.
Investigating the Science Behind Psilocybin
A research partnership involving PICMI, S&G Labs, and Alan Wu, PhD, at the University of California, San Francisco (UCSF), is looking at both biological and cognitive responses to psilocybin. The study tracks brain-derived neurotrophic factor (BDNF), pro-BDNF, psilocin pharmacokinetics, and standardized cognitive assessments. S&G Labs is handling the laboratory and analytical work according to the study protocol and the roles assigned to each participating lab. By pairing biological markers with cognitive measurements, the team hopes to see whether physiological changes line up with shifts in cognitive performance.
For Dr. Lynn Puana, this research is a chance to build a more solid scientific base for psychedelic medicine and pinpoint questions that still need answers. While the results could guide future work, more controlled studies are needed before any conclusions can be drawn about effectiveness, safety, or appropriate use.
Translating Emerging Evidence Into Clinical Practice
At PICMI in Denver, Dr. Lynn Puana leads a broad approach to brain health and mental wellness that includes medical screening, personalized care plans, preparation and integration support, and licensed psilocybin facilitation under Colorado’s regulated natural medicine framework. When clinically indicated, patient assessments can include cognitive testing, quantitative electroencephalography (qEEG) brain mapping, neurofeedback, genomic testing, and other diagnostic tools. These assessments are meant to give a fuller picture of each patient’s health rather than relying on any single test or treatment.
With over two decades of experience in internal medicine, interventional pain management, and addiction medicine, Dr. Lynn Puana brings a practical clinical lens to questions about chronic pain, trauma, cognitive decline, and complex medical conditions. Her approach prioritizes careful patient selection, consistent follow-up, and ongoing outcome tracking.
Connecting Patient Experiences With Medical Education
PICMI also captures patient perspectives through testimonial videos and podcast conversations with individuals who discuss their experiences with depression, chronic pain, trauma, and neurological illness. These stories provide valuable insight into what patients go through—but they are meant to complement, not replace, objective outcome data and controlled clinical research.
On October 2, 2026, Dr. Lynn Puana presented at the Texas Pain Society meeting in Dallas, where she discussed emerging psilocybin research and its possible implications for chronic pain, neuroplasticity, central sensitization, and the psychological aspects of persistent pain.
“Responsible psychedelic medicine requires a connection between biological research, thoughtful clinical care, and the experiences of patients,” said Dr. Lynn Puana, MD. “The goal is to investigate these treatments carefully, understand their limitations, and build an evidence base that helps inform future medical decisions.”
About PICMI and S&G Labs
Premier Integrative & Cognitive Medical Institute (PICMI) offers integrative, physician-led services focused on brain health, cognitive assessment, and personalized mental wellness in Denver, Colorado. S&G Labs provides laboratory and analytical expertise for research initiatives examining biological responses to emerging treatments. Together with research collaborators, these organizations aim to connect scientific investigation, clinical assessment, and patient-centered care. Their shared mission is to advance understanding of complex health conditions through evidence-informed evaluation and continued research.
Website: https://premiercognitive.com
Dr. Lynn Puana
Premier Integrative & Cognitive Medical Institute
staff@premiercognitive.com
Visit us on social media:
Facebook
Why it matters: As psychedelic medicine moves from fringe to mainstream, studies like this one are critical for establishing whether these treatments actually work and for whom. The emphasis on rigorous lab analysis and physician oversight could set a standard for how the field develops—and help protect patients from unproven claims.
